Pharmacokinetic profile and effect on bone markers and muscle strength of two daily dosage regimens of calcifediol in osteopenic/osteoporotic postmenopausal women.
Calcifediol
Muscle strength
Myostatin
Osteoporosis
Vitamin D deficiency
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
19
10
2020
accepted:
08
12
2020
pubmed:
29
1
2021
medline:
14
9
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
At present, although cholecalciferol represents the form of vitamin D of choice for the treatment of vitamin D deficiency, there is a growing interest in calcifediol. This study aimed to evaluate the efficacy and the safety of two different daily doses of calcifediol. Fifty osteopenic/osteoporotic women with serum levels of 25-hydroxyvitamin D (25OHD) between 10 and 20 ng/ml were randomized to a 6-month treatment with oral calcifediol 20 µg/day (n = 25) or oral calcifediol 30 µg/day (n = 25). In all, we measured the time course of the levels of 25OHD and other biochemical parameters. Moreover, we evaluated handgrip strength and serum levels of myostatin. The peak increase in 25OHD levels was reached after 90 days of treatment in group 1 (59.3 ng/ml) and after only 60 days in group 2 (72.3 ng/ml); thereafter in both groups, the levels of 25OHD showed a tendency towards stabilization. After 30 days, all the patients treated with 30 µg/day had values of 25OHD > 30 ng/ml. Handgrip strength showed a modest but progressive increase which reached the statistical significance in the 30 µg/day group. This latter group also presented a modest and non-significant decrease in serum levels of myostatin. Calcifediol is able to rapidly normalize the vitamin D deficiency, and the 30 µg daily dosage could be suggested in those patients who need to rapidly reach optimal 25OHD levels. Moreover, the 6-month treatment with calcifediol at a dose of 30 µg results in a modest but significant increase in upper limb strength.
Sections du résumé
BACKGROUND
BACKGROUND
At present, although cholecalciferol represents the form of vitamin D of choice for the treatment of vitamin D deficiency, there is a growing interest in calcifediol.
AIMS
OBJECTIVE
This study aimed to evaluate the efficacy and the safety of two different daily doses of calcifediol.
METHODS
METHODS
Fifty osteopenic/osteoporotic women with serum levels of 25-hydroxyvitamin D (25OHD) between 10 and 20 ng/ml were randomized to a 6-month treatment with oral calcifediol 20 µg/day (n = 25) or oral calcifediol 30 µg/day (n = 25). In all, we measured the time course of the levels of 25OHD and other biochemical parameters. Moreover, we evaluated handgrip strength and serum levels of myostatin.
RESULTS
RESULTS
The peak increase in 25OHD levels was reached after 90 days of treatment in group 1 (59.3 ng/ml) and after only 60 days in group 2 (72.3 ng/ml); thereafter in both groups, the levels of 25OHD showed a tendency towards stabilization. After 30 days, all the patients treated with 30 µg/day had values of 25OHD > 30 ng/ml. Handgrip strength showed a modest but progressive increase which reached the statistical significance in the 30 µg/day group. This latter group also presented a modest and non-significant decrease in serum levels of myostatin.
CONCLUSIONS
CONCLUSIONS
Calcifediol is able to rapidly normalize the vitamin D deficiency, and the 30 µg daily dosage could be suggested in those patients who need to rapidly reach optimal 25OHD levels. Moreover, the 6-month treatment with calcifediol at a dose of 30 µg results in a modest but significant increase in upper limb strength.
Identifiants
pubmed: 33506314
doi: 10.1007/s40520-020-01779-7
pii: 10.1007/s40520-020-01779-7
pmc: PMC8429405
doi:
Substances chimiques
Vitamin D
1406-16-2
Cholecalciferol
1C6V77QF41
Calcifediol
P6YZ13C99Q
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2539-2547Informations de copyright
© 2021. The Author(s).
Références
Adv Ther. 2017 Mar;34(3):744-752
pubmed: 28205055
Endocrinology. 2016 Jan;157(1):98-111
pubmed: 26469137
Nutrients. 2019 Nov 15;11(11):
pubmed: 31731651
Clin Nutr. 2018 Jun;37(3):808-814
pubmed: 28433267
Osteoporos Int. 1998;8(3):222-30
pubmed: 9797906
Eur J Clin Nutr. 2002 Jan;56(1):21-30
pubmed: 11840176
J Steroid Biochem Mol Biol. 2011 Sep;126(3-5):72-7
pubmed: 21605672
BMJ. 2009 Oct 01;339:b3692
pubmed: 19797342
Endocrinology. 2011 Aug;152(8):2976-86
pubmed: 21673099
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1133-1140
pubmed: 28187226
Hormones (Athens). 2019 Mar;18(1):3-5
pubmed: 29949127
Osteoporos Int. 2012 Oct;23(10):2479-87
pubmed: 22237813
Hormones (Athens). 2020 Jun;19(2):81-96
pubmed: 31919677
Nutrition. 2015 Jul-Aug;31(7-8):931-4
pubmed: 26015388
Endocrinology. 2014 Feb;155(2):347-57
pubmed: 24280059
Osteoporos Int. 2018 Aug;29(8):1697-1711
pubmed: 29713796
J Clin Endocrinol Metab. 2014 Nov;99(11):4336-45
pubmed: 25033068
J Bone Miner Metab. 2019 Sep;37(5):920-927
pubmed: 30790083
J Clin Endocrinol Metab. 2011 Jan;96(1):53-8
pubmed: 21118827
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Nutrients. 2020 May 31;12(6):
pubmed: 32486496
Osteoporos Int. 2017 Nov;28(11):3239-3249
pubmed: 28815282
JAMA Intern Med. 2016 Feb;176(2):175-83
pubmed: 26747333
Bone. 2014 Feb;59:14-9
pubmed: 24516879
Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42
pubmed: 27662240
Endocrine. 2015 Sep;50(1):12-26
pubmed: 25931412
Osteoporos Int. 2009 Feb;20(2):239-44
pubmed: 18551242
Reumatismo. 2016 Jun 23;68(1):1-39
pubmed: 27339372
J Steroid Biochem Mol Biol. 2016 Nov;164:205-208
pubmed: 26829558
Bone. 2012 Jul;51(1):54-8
pubmed: 22487299
Osteoporos Int. 2011 Mar;22(3):859-71
pubmed: 20924748
J Bone Miner Res. 2012 Jan;27(1):160-9
pubmed: 22028071
Am J Clin Nutr. 2012 Jun;95(6):1350-6
pubmed: 22552038
JAMA. 2010 May 12;303(18):1815-22
pubmed: 20460620